Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 232 entries
Sorted by: Best Match Show Resources per page
Germline .

Frontiers in endocrinology

Hansen AR, Borgwardt L, Rasmussen ÅK, Godballe C, Poulsen MM, Vieira FG, Mathiesen JS, Rossing M.
PMID: 34925234
Front Endocrinol (Lausanne). 2021 Dec 01;12:764512. doi: 10.3389/fendo.2021.764512. eCollection 2021.

Activating variants in the receptor tyrosine kinase

Cite
Hansen AR, Borgwardt L, Rasmussen ÅK, et al. Germline . Front Endocrinol (Lausanne). 2021;12:764512doi: 10.3389/fendo.2021.764512.
Hansen, A. R., Borgwardt, L., Rasmussen, �. �. K., Godballe, C., Poulsen, M. M., Vieira, F. G., Mathiesen, J. S., & Rossing, M. (2021). Germline . Frontiers in endocrinology, 12764512. https://doi.org/10.3389/fendo.2021.764512
Hansen, Anna Reimer, et al. "Germline ." Frontiers in endocrinology vol. 12 (2021): 764512. doi: https://doi.org/10.3389/fendo.2021.764512
Hansen AR, Borgwardt L, Rasmussen ÅK, Godballe C, Poulsen MM, Vieira FG, Mathiesen JS, Rossing M. Germline . Front Endocrinol (Lausanne). 2021 Dec 01;12:764512. doi: 10.3389/fendo.2021.764512. eCollection 2021. PMID: 34925234; PMCID: PMC8672160.
Copy Download .nbib Format: NLM
Effect of Liraglutide on Vascular Inflammation Evaluated by [.

Diagnostics (Basel, Switzerland)

Zobel EH, Ripa RS, von Scholten BJ, Curovic VR, Diaz LJ, Hansen TW, Rossing P, Kjaer A.
PMID: 34441365
Diagnostics (Basel). 2021 Aug 08;11(8). doi: 10.3390/diagnostics11081431.

Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26...

Cite
Zobel EH, Ripa RS, von Scholten BJ, et al. Effect of Liraglutide on Vascular Inflammation Evaluated by [. Diagnostics (Basel). 2021;11(8)doi: 10.3390/diagnostics11081431.
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Diaz, L. J., Hansen, T. W., Rossing, P., & Kjaer, A. (2021). Effect of Liraglutide on Vascular Inflammation Evaluated by [. Diagnostics (Basel, Switzerland), 11(8), . https://doi.org/10.3390/diagnostics11081431
Zobel, Emilie H, et al. "Effect of Liraglutide on Vascular Inflammation Evaluated by [." Diagnostics (Basel, Switzerland) vol. 11,8 (2021). doi: https://doi.org/10.3390/diagnostics11081431
Zobel EH, Ripa RS, von Scholten BJ, Curovic VR, Diaz LJ, Hansen TW, Rossing P, Kjaer A. Effect of Liraglutide on Vascular Inflammation Evaluated by [. Diagnostics (Basel). 2021 Aug 08;11(8). doi: 10.3390/diagnostics11081431. PMID: 34441365; PMCID: PMC8391433.
Copy Download .nbib Format: NLM
For which patient subgroups are there positive outcomes from a medication review? A systematic review.

Pharmacy practice

Abrahamsen B, Hansen RN, Rossing C.
PMID: 33224322
Pharm Pract (Granada). 2020 Oct-Dec;18(4):1976. doi: 10.18549/PharmPract.2020.4.1976. Epub 2020 Oct 27.

BACKGROUND: A medication review is a possibility to assess and optimise a patient's medicine. A model that includes a medication review and a follow-up seem to provide the best results. However, it is not known whether specific subgroups of...

Cite
Abrahamsen B, Hansen RN, Rossing C. For which patient subgroups are there positive outcomes from a medication review? A systematic review. Pharm Pract (Granada). 2020;18(4):1976doi: 10.18549/PharmPract.2020.4.1976.
Abrahamsen, B., Hansen, R. N., & Rossing, C. (2020). For which patient subgroups are there positive outcomes from a medication review? A systematic review. Pharmacy practice, 18(4), 1976. https://doi.org/10.18549/PharmPract.2020.4.1976
Abrahamsen, Bjarke, et al. "For which patient subgroups are there positive outcomes from a medication review? A systematic review." Pharmacy practice vol. 18,4 (2020): 1976. doi: https://doi.org/10.18549/PharmPract.2020.4.1976
Abrahamsen B, Hansen RN, Rossing C. For which patient subgroups are there positive outcomes from a medication review? A systematic review. Pharm Pract (Granada). 2020 Oct-Dec;18(4):1976. doi: 10.18549/PharmPract.2020.4.1976. Epub 2020 Oct 27. PMID: 33224322; PMCID: PMC7672485.
Copy Download .nbib Format: NLM
[No title available]

Journal of medical genetics

Fadaie Z, Whelan L, Dockery A, Li CHZ, van den Born LI, Hoyng CB, Gilissen C, Corominas J, Rowlands C, Megaw R, Lampe AK, Cremers FPM, Farrar GJ, Ellingford JM, Kenna PF, Roosing S.
PMID: 33910932
J Med Genet. 2021 Apr 28; doi: 10.1136/jmedgenet-2020-107626. Epub 2021 Apr 28.

BACKGROUND: Inherited retinal diseases (IRDs) can be caused by variants in >270 genes. The Bardet-Biedl syndrome 1 (METHODS: Whole genome sequencing was performed for three unrelated monoallelic RESULTS: Clinical assessments of probands showed that all individuals displayed non-syndromic RP...

Cite
Fadaie Z, Whelan L, Dockery A, et al. . J Med Genet. 2021;doi: 10.1136/jmedgenet-2020-107626.
Fadaie, Z., Whelan, L., Dockery, A., Li, C. H. Z., van den Born, L. I., Hoyng, C. B., Gilissen, C., Corominas, J., Rowlands, C., Megaw, R., Lampe, A. K., Cremers, F. P. M., Farrar, G. J., Ellingford, J. M., Kenna, P. F., & Roosing, S. (2021). . Journal of medical genetics, . https://doi.org/10.1136/jmedgenet-2020-107626
Fadaie, Zeinab, et al. "." Journal of medical genetics vol. (2021). doi: https://doi.org/10.1136/jmedgenet-2020-107626
Fadaie Z, Whelan L, Dockery A, Li CHZ, van den Born LI, Hoyng CB, Gilissen C, Corominas J, Rowlands C, Megaw R, Lampe AK, Cremers FPM, Farrar GJ, Ellingford JM, Kenna PF, Roosing S. . J Med Genet. 2021 Apr 28; doi: 10.1136/jmedgenet-2020-107626. Epub 2021 Apr 28. PMID: 33910932.
Copy Download .nbib Format: NLM
The authors reply.

Kidney international

Caramori ML, Tuttle KR, Tandon N, Tunnicliffe DJ, de Boer IH, Rossing P.
PMID: 34906418
Kidney Int. 2021 Dec 11; doi: 10.1016/j.kint.2021.11.019. Epub 2021 Dec 11.

No abstract available.

Cite
Caramori ML, Tuttle KR, Tandon N, et al. The authors reply. Kidney Int. 2021;doi: 10.1016/j.kint.2021.11.019.
Caramori, M. L., Tuttle, K. R., Tandon, N., Tunnicliffe, D. J., de Boer, I. H., Rossing, P. (2021). The authors reply. Kidney international, . https://doi.org/10.1016/j.kint.2021.11.019
Caramori, M Luiza, et al. "The authors reply." Kidney international vol. (2021). doi: https://doi.org/10.1016/j.kint.2021.11.019
Caramori ML, Tuttle KR, Tandon N, Tunnicliffe DJ, de Boer IH, Rossing P. The authors reply. Kidney Int. 2021 Dec 11; doi: 10.1016/j.kint.2021.11.019. Epub 2021 Dec 11. PMID: 34906418.
Copy Download .nbib Format: NLM
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [.

Frontiers in endocrinology

Jensen JK, Zobel EH, von Scholten BJ, Rotbain Curovic V, Hansen TW, Rossing P, Kjaer A, Ripa RS.
PMID: 34917038
Front Endocrinol (Lausanne). 2021 Nov 30;12:790405. doi: 10.3389/fendo.2021.790405. eCollection 2021.

BACKGROUND: Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using...

Cite
Jensen JK, Zobel EH, von Scholten BJ, et al. Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [. Front Endocrinol (Lausanne). 2021;12:790405doi: 10.3389/fendo.2021.790405.
Jensen, J. K., Zobel, E. H., von Scholten, B. J., Rotbain Curovic, V., Hansen, T. W., Rossing, P., Kjaer, A., & Ripa, R. S. (2021). Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [. Frontiers in endocrinology, 12790405. https://doi.org/10.3389/fendo.2021.790405
Jensen, Jacob K, et al. "Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [." Frontiers in endocrinology vol. 12 (2021): 790405. doi: https://doi.org/10.3389/fendo.2021.790405
Jensen JK, Zobel EH, von Scholten BJ, Rotbain Curovic V, Hansen TW, Rossing P, Kjaer A, Ripa RS. Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [. Front Endocrinol (Lausanne). 2021 Nov 30;12:790405. doi: 10.3389/fendo.2021.790405. eCollection 2021. PMID: 34917038; PMCID: PMC8669791.
Copy Download .nbib Format: NLM
Highly impaired platelet ultrastructure in two families with novel .

Platelets

Leinoe E, Kjaersgaard M, Zetterberg E, Ostrowski S, Greinacher A, Rossing M.
PMID: 32419556
Platelets. 2021 May 19;32(4):492-497. doi: 10.1080/09537104.2020.1764921. Epub 2020 May 18.

Heterozygous variants in the IKZF5 gene, encoding transcription factor Pegasus, were recently discovered to be causal of inherited thrombocytopenia (IT). We screened 90 patients suspected of inherited thrombocytopenia for variants in 101 genes associated with inherited bleeding disorders and...

Cite
Leinoe E, Kjaersgaard M, Zetterberg E, et al. Highly impaired platelet ultrastructure in two families with novel . Platelets. 2020;32(4):492-497doi: 10.1080/09537104.2020.1764921.
Leinoe, E., Kjaersgaard, M., Zetterberg, E., Ostrowski, S., Greinacher, A., & Rossing, M. (2021). Highly impaired platelet ultrastructure in two families with novel . Platelets, 32(4), 492-497. https://doi.org/10.1080/09537104.2020.1764921
Leinoe, Eva, et al. "Highly impaired platelet ultrastructure in two families with novel ." Platelets vol. 32,4 (2021): 492-497. doi: https://doi.org/10.1080/09537104.2020.1764921
Leinoe E, Kjaersgaard M, Zetterberg E, Ostrowski S, Greinacher A, Rossing M. Highly impaired platelet ultrastructure in two families with novel . Platelets. 2021 May 19;32(4):492-497. doi: 10.1080/09537104.2020.1764921. Epub 2020 May 18. PMID: 32419556.
Copy Download .nbib Format: NLM
Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes.

Frontiers in endocrinology

Tofte N, Suvitaival T, Trost K, Mattila IM, Theilade S, Winther SA, Ahluwalia TS, Frimodt-Møller M, Legido-Quigley C, Rossing P.
PMID: 31824430
Front Endocrinol (Lausanne). 2019 Nov 22;10:818. doi: 10.3389/fendo.2019.00818. eCollection 2019.

No abstract available.

Cite
Tofte N, Suvitaival T, Trost K, et al. Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. Front Endocrinol (Lausanne). 2019;10:818doi: 10.3389/fendo.2019.00818.
Tofte, N., Suvitaival, T., Trost, K., Mattila, I. M., Theilade, S., Winther, S. A., Ahluwalia, T. S., Frimodt-Møller, M., Legido-Quigley, C., & Rossing, P. (2019). Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. Frontiers in endocrinology, 10818. https://doi.org/10.3389/fendo.2019.00818
Tofte, Nete, et al. "Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes." Frontiers in endocrinology vol. 10 (2019): 818. doi: https://doi.org/10.3389/fendo.2019.00818
Tofte N, Suvitaival T, Trost K, Mattila IM, Theilade S, Winther SA, Ahluwalia TS, Frimodt-Møller M, Legido-Quigley C, Rossing P. Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. Front Endocrinol (Lausanne). 2019 Nov 22;10:818. doi: 10.3389/fendo.2019.00818. eCollection 2019. PMID: 31824430; PMCID: PMC6883958.
Copy Download .nbib Format: NLM
A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data.

Cancers

Gabrielaite M, Torp MH, Rasmussen MS, Andreu-Sánchez S, Vieira FG, Pedersen CB, Kinalis S, Madsen MB, Kodama M, Demircan GS, Simonyan A, Yde CW, Olsen LR, Marvig RL, Østrup O, Rossing M, Nielsen FC, Winther O, Bagger FO.
PMID: 34944901
Cancers (Basel). 2021 Dec 14;13(24). doi: 10.3390/cancers13246283.

Copy-number variations (CNVs) have important clinical implications for several diseases and cancers. Relevant CNVs are hard to detect because common structural variations define large parts of the human genome. CNV calling from short-read sequencing would allow single protocol full...

Cite
Gabrielaite M, Torp MH, Rasmussen MS, et al. A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246283.
Gabrielaite, M., Torp, M. H., Rasmussen, M. S., Andreu-Sánchez, S., Vieira, F. G., Pedersen, C. B., Kinalis, S., Madsen, M. B., Kodama, M., Demircan, G. S., Simonyan, A., Yde, C. W., Olsen, L. R., Marvig, R. L., Østrup, O., Rossing, M., Nielsen, F. C., Winther, O., & Bagger, F. O. (2021). A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data. Cancers, 13(24), . https://doi.org/10.3390/cancers13246283
Gabrielaite, Migle, et al. "A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246283
Gabrielaite M, Torp MH, Rasmussen MS, Andreu-Sánchez S, Vieira FG, Pedersen CB, Kinalis S, Madsen MB, Kodama M, Demircan GS, Simonyan A, Yde CW, Olsen LR, Marvig RL, Østrup O, Rossing M, Nielsen FC, Winther O, Bagger FO. A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data. Cancers (Basel). 2021 Dec 14;13(24). doi: 10.3390/cancers13246283. PMID: 34944901.
Copy Download .nbib Format: NLM
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN

Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL.
PMID: 34732509
J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 03.

BACKGROUND: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD.METHODS: This RESULTS: Over 2.6 years' median...

Cite
Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2021;33(1):225-237doi: 10.1681/ASN.2021070942.
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., Wilson, D. J., Bakris, G. L. (2022). Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology : JASN, 33(1), 225-237. https://doi.org/10.1681/ASN.2021070942
Agarwal, Rajiv, et al. "Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial." Journal of the American Society of Nephrology : JASN vol. 33,1 (2022): 225-237. doi: https://doi.org/10.1681/ASN.2021070942
Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 03. PMID: 34732509.
Copy Download .nbib Format: NLM
Hypertonic Saline for Moderate Traumatic Brain Injury: A Scoping Review of Impact on Neurological Deterioration.

Neurotrauma reports

Rossong H, Hasen M, Ahmed B, Zeiler FA, Dhaliwal P.
PMID: 33381773
Neurotrauma Rep. 2020 Dec 15;1(1):253-260. doi: 10.1089/neur.2020.0056. eCollection 2020.

Hypertonic saline (HTS) is a commonly administered agent for intracranial pressure (ICP) control in traumatic brain injury (TBI). The literature on its use is mainly in moderate/severe TBI where invasive ICP monitoring is present. The role of HTS in...

Cite
Rossong H, Hasen M, Ahmed B, et al. Hypertonic Saline for Moderate Traumatic Brain Injury: A Scoping Review of Impact on Neurological Deterioration. Neurotrauma Rep. 2020;1(1):253-260doi: 10.1089/neur.2020.0056.
Rossong, H., Hasen, M., Ahmed, B., Zeiler, F. A., & Dhaliwal, P. (2020). Hypertonic Saline for Moderate Traumatic Brain Injury: A Scoping Review of Impact on Neurological Deterioration. Neurotrauma reports, 1(1), 253-260. https://doi.org/10.1089/neur.2020.0056
Rossong, Heather, et al. "Hypertonic Saline for Moderate Traumatic Brain Injury: A Scoping Review of Impact on Neurological Deterioration." Neurotrauma reports vol. 1,1 (2020): 253-260. doi: https://doi.org/10.1089/neur.2020.0056
Rossong H, Hasen M, Ahmed B, Zeiler FA, Dhaliwal P. Hypertonic Saline for Moderate Traumatic Brain Injury: A Scoping Review of Impact on Neurological Deterioration. Neurotrauma Rep. 2020 Dec 15;1(1):253-260. doi: 10.1089/neur.2020.0056. eCollection 2020. PMID: 33381773; PMCID: PMC7769038.
Copy Download .nbib Format: NLM
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.

Pharmacological research

Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH.
PMID: 34700018
Pharmacol Res. 2021 Oct 23;105954. doi: 10.1016/j.phrs.2021.105954. Epub 2021 Oct 23.

Abemaciclib is the third cyclin-dependent kinase (CDK) 4/6 inhibitor approved for the treatment of breast cancer and currently under investigation for other malignancies, including brain cancer. Primarily CYP3A4 metabolizes abemaciclib, forming three active metabolites (M2, M20 and M18) that...

Cite
Martínez-Chávez A, Loos NHC, Lebre MC, et al. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacol Res. 2021;105954doi: 10.1016/j.phrs.2021.105954.
Martínez-Chávez, A., Loos, N. H. C., Lebre, M. C., Tibben, M. M., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2021). ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacological research, 105954. https://doi.org/10.1016/j.phrs.2021.105954
Martínez-Chávez, Alejandra, et al. "ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites." Pharmacological research vol. (2021): 105954. doi: https://doi.org/10.1016/j.phrs.2021.105954
Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacol Res. 2021 Oct 23;105954. doi: 10.1016/j.phrs.2021.105954. Epub 2021 Oct 23. PMID: 34700018.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 232 entries